Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria. Review of the applications is expected to by completed in Q4 2025, ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

The multinational drug manufacturer headquartered in Israel ... The commission found Teva either tried to slow down ...

The generics manufacturer Teva Pharmaceuticals has failed to persuade a Federal Circuit appeals court to maintain 180 days of exclusivity for a generic version of Pfizer's antidepressant ...